JTCS Speed Up Your Browser
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lundin, L.
Right arrow Articles by Oberg, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lundin, L.
Right arrow Articles by Oberg, K.

The Journal of Thoracic and Cardiovascular Surgery, Vol 100, 552-561, Copyright © 1990 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association


ARTICLES

Surgical treatment of carcinoid heart disease

L Lundin, HE Hansson, J Landelius and K Oberg
Department of Cardiology, University Hospital, Uppsala, Sweden.

Right heart failure in patients with carcinoid heart disease is a serious prognostic sign. Consideration and adequate timing of valvular operations seem essential for the postoperative outcome. Without any relation to duration or progression of the metastasizing tumor disease, right heart failure developed and increased rapidly for a period of 12 to 17 months in four patients with classic carcinoid syndrome. Invasive hemodynamic and cardiac ultrasound investigations revealed severe carcinoid heart disease, and medical decompensation treatment gradually failed. Tricuspid and pulmonic valve replacement operations resulted in dramatic improvement in three of the patients, and these patients were still free of cardiac symptoms 10, 12, and 38 months postoperatively. One patient died 5 days postoperatively probably of septicemia. The preoperative and postoperative development of the cardiac disease is evaluated clinically, by cardiac ultrasound and plasma atrial natriuretic peptide concentrations, and related to the tumor disease. Surgical anatomy and operative technique are reported, and the beneficial value of prophylactic treatment of the effects of tumor- released vasoactive substances by a somatostatin analog is emphasized.


This article has been cited by other articles:


Home page
Anesth. Analg.Home page
T. N. Weingarten, M. D. Abel, H. M. Connolly, D. R. Schroeder, and H. V. Schaff
Intraoperative Management of Patients with Carcinoid Heart Disease Having Valvular Surgery: A Review of One Hundred Consecutive Cases
Anesth. Analg., November 1, 2007; 105(5): 1192 - 1199.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. A. Robiolio, V. H. Rigolin, J. S. Wilson, J. K. Harrison, L. L. Sanders, T. M. Bashore, and J. M. Feldman
Carcinoid Heart Disease : Correlation of High Serotonin Levels With Valvular Abnormalities Detected by Cardiac Catheterization and Echocardiography
Circulation, August 15, 1995; 92(4): 790 - 795.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1990 by The American Association for Thoracic Surgery.